3HELIX INC

SALT LAKE CITY, UT · Founded 2023 · CIK 0002001622 · Biotech · Private

Collagen Hybridizing Peptides (CHP) for direct detection of denatured collagen in damaged tissue

3helix.com →
Grants
$1.7M
4 awards
Sector median: 1
Raised
$12M
2 Form D · Sep 2026
1 months since last filing
Contracts
—
No federal contracts on record
Patents
18
0 granted · 18 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · New Peptide Reagent for Imaging Denatured Collagen in Histopathology$149,623
Federal grantDepartment of Health and Human Services · Phase I · New Peptide Reagent for Imaging Denatured Collagen in Histopathology$149,623
Federal grantDepartment of Health and Human Services · Phase II · Novel peptide reagents for imaging damage to collagen structure in histopathology and in vivo$704,620
Federal grantDepartment of Health and Human Services · Phase II · Novel peptide reagents for imaging damage to collagen structure in histopathology and in vivo$713,771
Private capital raisedForm D · SEC$3,749,987
Private capital raisedForm D · SEC$7,835,028
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1539Purilogics, LLC——
1540Biophytis SA—$4.2M
1541Potrero Hill Therapeutics——
15423HELIX INC—$12M
1543Adcytherix——
1544WALIA, RAMPYARI——
1545Typewriter Therapeutics—$56M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Michael FugmanDirector
  • Michael KirknessDirector · Executive Officer
  • Noah NasserDirector
  • Michael YuDirector

Patents

USPTO · 0 granted of 18
  • Systems and Methods for Detecting Fibrosisapplication
  • Biologically Active Collagen Hybridizing Peptidesapplication
  • Methods for Using Collagen Hybridizing Peptides to Determine Collagen Contentapplication
  • Collagen Hybridization Peptides Having A Sequence Comprising Lair And/or Rage Binding Sequence And Use Thereofapplication
  • Anti-Inflammatory Bio-Active Collagen Hybridizing Peptides and Methods of Using Thereofapplication
  • Collagen hybridization peptides having modified C-terminal and use thereofapplication
  • Collagen hybridization peptides having a sequence comprising citrullinated LAIR binding sequence and use thereofapplication
  • Collagen hybridization peptides having a sequence comprising LAIR and/or RAGE binding sequence and use thereofapplication
  • Anti-inflammatory Bio-active Collagen Hybridizing Peptides And Methods Of Using Thereofapplication
  • Anti-Inflammatory Bio-Active Collagen Hybridizing Peptides and Methods of Using Thereofapplication
  • Biologically Active Collagen Hybridizing Peptidesapplication
  • Systems And Methods For Detecting Fibrosisapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.